Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

Opinion
Video

This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.

Recent Videos
4 experts in this video
4 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content